Today: 13 June 2026
Salesforce stock heads into Monday: Spring ’26 rollout and earnings clock put CRM back in focus
11 January 2026
2 mins read

Salesforce stock heads into Monday: Spring ’26 rollout and earnings clock put CRM back in focus

New York, January 11, 2026, 14:38 EST — Market closed.

  • Salesforce shares dipped 0.23% on Friday, closing at $259.94.
  • Salesforce announced its Spring ’26 product update, featuring fresh AI, data, and automation capabilities, will begin rolling out on Feb. 23.
  • Salesforce is set to release its earnings on Feb. 25, after the market closes, per Yahoo Finance’s earnings calendar.

Salesforce, Inc. shares slipped roughly 0.2% to close at $259.94 on Friday, following the company’s announcement of its Spring ’26 product release. The update, featuring a suite of new tools, is set to begin rolling out on Feb. 23. U.S. markets will resume trading Monday after the weekend hiatus.

This update is crucial as Salesforce pushes to convert its “AI agents” concept into revenue before the upcoming earnings release. These AI agents—software bots—handle routine tasks within business apps, cutting down on manual labor.

Investors are pressing a straightforward question: do the new tools drive renewals, expansions, and new deals, or are they just impressive demos? In the coming weeks, a product rollout and earnings report should provide at least part of the answer.

In early December, Salesforce boosted its fiscal 2026 revenue forecast to a range of $41.45 billion to $41.55 billion. The company reported that current remaining performance obligations, which track contracted revenue expected over the next 12 months, jumped 11% to $29.4 billion. Annual recurring revenue (ARR) for Agentforce and Data 360 hit nearly $1.4 billion. CEO Marc Benioff confirmed the company was “raising fiscal year 2026 revenue guidance,” while CFO Robin Washington said the strong adoption “reinforces our path” to reaching longer-term goals. Salesforce Investor Relations

Risk appetite remains solid. The S&P 500 and Dow closed Friday at new highs despite a mixed U.S. jobs report, with the Nasdaq posting gains as well.

Salesforce announced that its Spring package brings an AI-powered sales workspace, service tools aimed at catching problems before they turn into support cases, and a two-way email feature allowing automated agents to handle routine replies. The company also spotlighted an “Agentforce Builder” interface designed to accelerate how firms create and test agents.

Enterprise software stocks diverged sharply on Friday. Oracle jumped 4.95%, but ServiceNow slipped 3%, highlighting a patchwork of individual company drivers instead of a unified sector move.

Salesforce shares have dropped 18.5% in the last 52 weeks, per Yahoo Finance, currently trading far below their 52-week peak of $367.09.

The Spring rollout kicks off in late February, and traders will be watching closely to see if customers are actively using the new tools rather than just dabbling. During the earnings call, the focus typically lands on subscription growth, backlog developments, operating margin, and any news on share buybacks.

Yet, new product launches don’t automatically translate into spending. If companies cut back on tech budgets or put off upgrades, the boost from these tools might come later—or might never materialize.

Next week packs in major U.S. lenders kicking off earnings season, alongside a slew of conferences and economic reports that could reshape rate forecasts. Software stocks will be sensitive to these moves, reacting not just to company updates but also to yield fluctuations.

Salesforce has two key dates ahead: Feb. 23 marks the start of the Spring ’26 release rollout, while Feb. 25 is when Wall Street anticipates the company will report earnings and update its guidance.

Stock Market Today

  • Ascletis Pharma Stock Falls 41.6% in a Month, Valuation Mixed Amid Losses
    June 13, 2026, 12:37 AM EDT. Ascletis Pharma (SEHK:1672) shares dropped 4.4% last week and 41.6% over the past month, raising questions about its valuation. The stock trades at a price-to-book (P/B) ratio of 4.7x, above the Hong Kong Biotech sector average of 3.2x but below a peer group average of 12.5x, signaling mixed valuation metrics. The company remains unprofitable with a negative return on equity of 18.61%, making earnings-based measures less relevant. While longer-term returns remain positive, recent revenue and net income weaknesses alongside ongoing losses pose risks. Investors are advised to review underlying data carefully before deciding on Ascletis Pharma's stock prospects amid a cautious market sentiment.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
Tencent Holdings stock: buyback keeps pressure on bears as AI bottleneck warning hits tape
Previous Story

Tencent Holdings stock: buyback keeps pressure on bears as AI bottleneck warning hits tape

UiPath stock: CEO share sale filing puts PATH in focus ahead of a busy week
Next Story

UiPath stock: CEO share sale filing puts PATH in focus ahead of a busy week

Go toTop